Title: | Superselective intra-arterial cisplatin infusion and concomitant radiotherapy for maxillary sinus cancer |
Authors: | Homma, Akihiro Browse this author →KAKEN DB |
Sakashita, Tomohiro Browse this author |
Yoshida, Daisuke Browse this author |
Onimaru, Rikiya Browse this author →KAKEN DB |
Tsuchiya, Kazuhiko Browse this author |
Suzuki, Fumiyuki Browse this author |
Yasuda, Koichi Browse this author |
Hatakeyama, Hiromitsu Browse this author →KAKEN DB |
Furusawa, Jun Browse this author |
Mizumachi, Takatsugu Browse this author |
Kano, Satoshi Browse this author |
Inamura, Naoya Browse this author |
Taki, Shigenari Browse this author |
Shirato, Hiroki Browse this author →KAKEN DB |
Fukuda, Satoshi Browse this author →KAKEN DB |
Keywords: | intra-arterial |
cisplatin |
maxillary sinus |
chemotherapy |
radiotherapy |
Issue Date: | 10-Dec-2013 |
Publisher: | Nature publishing group |
Journal Title: | British journal of cancer |
Volume: | 109 |
Issue: | 12 |
Start Page: | 2980 |
End Page: | 2986 |
Publisher DOI: | 10.1038/bjc.2013.663 |
PMID: | 24196792 |
Abstract: | Background: The purpose of this study was to evaluate the efficacy of superselective cisplatin infusion with concomitant radiotherapy (RADPLAT) for previously untreated patients with the squamous cell carcinoma of maxillary sinus (SCC-MS). Methods: Between 1999 and 2010, 54 patients were given superselective intra-arterial infusions of cisplatin (100-120mgm(-2) per week) with simultaneous intra-venous infusions of thiosulfate to neutralise cisplatin toxicity and conventional radiotherapy (65-70 Gy). Results: One patient (1.9%) was diagnosed with T2, 14 (25.9%) with T3, 27 (50%) with T4a, and 12 (22.2%) with T4b disease. Lymph-node involvement was present in 12 patients (22.2%). During the median follow-up period of 6.4 years, the 5-year local progression-free and overall survival rates were 65.8 and 67.9% for all patients, respectively. No patient died as a result of treatment toxicity or experienced a cerebrovascular accident. Osteonecrosis (n-5), brain necrosis (n-1), and ocular/ visual problems (n = 14) were observed as late adverse reactions. Conclusion: We have shown excellent overall survival and local progression-free rate in SCC-MS patients treated by RADPLAT with acceptable rates of acute and late toxicity. A multi-institutional trial is needed to prove that this strategy is a feasible and effective approach for the treatment of SCC-MS. |
Type: | article (author version) |
URI: | http://hdl.handle.net/2115/56350 |
Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|